WILGO RESEARCH INDEX
Sermorelin
Sermorelin is GHRH(1-29)NH2, a 29-amino-acid fragment of growth hormone-releasing hormone that stimulates pituitary growth-hormone release. Its literature includes controlled human endocrine studies and older pediatric growth research.
GHRH(1-29)NH2Human endocrine studiesPediatric growth researchGH secretion
EVIDENCE MAP
What kind of evidence exists?
The evidence base is substantially older than for many peptides and is centered on endocrine physiology and pediatric growth disorders.
Older human data can be strong and still be narrow.
Sermorelin’s human literature is real, but it largely addresses endocrine testing and pediatric growth disorders. It does not automatically validate modern consumer claims outside those research contexts.
PUBLISHED LITERATURE
Selected studies.
Selected sources are grouped by study type so model limitations remain visible.
HUMAN · NORMAL VOLUNTEERS
Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men
Normal men showed dose-responsive GH release after GHRH(1-29)NH2; other measured pituitary and metabolic hormones were largely unchanged in the reported testing context.
HUMAN · PEDIATRIC
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
A multicenter open-label study treated previously untreated prepubertal GH-deficient children for up to one year and reported increased mean height velocity.
HUMAN · PEDIATRIC
Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children
Continuous administration augmented pulsatile GH secretion and promoted growth in some short, slowly growing children; growth rates returned toward pretreatment values after treatment stopped.
HUMAN · PEDIATRIC
Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity
Twice-daily GHRH analog therapy increased growth velocity during 12 months of treatment, followed by catch-down growth after cessation.
REVIEW · ENDOCRINOLOGY
Growth hormone releasing hormone
This review summarizes GHRH physiology, human GH responses, factors modifying the response, and early therapeutic research in short stature.
REFERENCES
Primary sources.
Direct PubMed links are used wherever possible.
Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal menPMID 2866496 · PubMed →
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapyPMID 8772599 · PubMed →
Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing childrenPMID 2140733 · PubMed →
Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocityPMID 7955460 · PubMed →
Growth hormone releasing hormonePMID 2429796 · PubMed →
Research-use notice: This resource summarizes published scientific literature for informational and research-reference purposes. It does not provide medical advice, dosing, reconstitution, injection, therapeutic, diagnostic, or other human-use instructions. WILGO products are intended for laboratory research use only and are not presented for human or animal consumption, diagnosis, treatment, prevention, weight management, cosmetic use, or self-administration.